Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol e-Device Self-Injection Study
NCT03357471Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease, sponsored by UCB. Started Nov 2017; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT03357471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357471.